7/5/2023 0 Comments Tabulo rasa![]() ![]() 43 rd Annual William Blair Growth Conference in Chicago, IL, June 6-8.Stifel 2023 Cross Sector Insight Conference in Boston, MA, June 6-7 and.Benchmark’s Healthcare House Call VIRTUAL One-on-One Conference, May 23.RBC Capital Markets 2023 Global Healthcare Conference in New York, NY, May 16-17.Members of TRHC’s executive team are currently expected to be present at the following conferences: To provide transparency into our financial results, we are providing the following operational metrics.Ī reconciliation of the projected adjusted EBITDA from continuing operations has been provided in this press release in the accompanying tables. ![]() An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.” $1.1 million (1.6% of revenue) in the first quarter of 2022.Ī reconciliation of certain financial measures with the most directly comparable financial measures calculated in accordance with generally accepted accounting principles in the United States (“GAAP”) has been provided in this press release in the accompanying tables. Adjusted EBITDA – Adjusted EBITDA from continuing operations of $4.7 million (5.4% of revenue) increased 337% vs. ![]() As previously announced on March 2, 2023, TRHC completed the sales of SinfoníaRx and DoseMe during the first quarter of 2023. Both periods include the SinfoníaRx and DoseMe businesses. GAAP net loss from discontinued operations (net of tax) of $8.8 million compares to a net loss of $7.8 million in the first quarter of 2022. the prior year was primarily driven by the higher gross profit noted above and a reduction in operating expenses.
0 Comments
Leave a Reply. |